Drug Trial News

RSS

One-month antibiotic regimen to prevent TB as safe, effective as nine-month therapy for HIV patients

A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial.

6 Mar 2018

New treatment shows promise to fight against serious inflammatory disease

Still's disease is a serious orphan disease manifested by high fevers, skin and joint involvement, including paralysis, as well as damage to other organs such as the liver or spleen. It is caused by a deregulation of the immune system triggering an acute inflammatory response.

27 Feb 2018

U.S. clinical sites evaluating antibody-based therapies to prevent two common bacterial infections

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting U.S. clinical sites participating in two ongoing international Phase 2 clinical trials evaluating investigational antibody-based therapies aimed at preventing potentially antibiotic-resistant infections.

23 Feb 2018

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.

From J&J Innovative Medicine 22 Feb 2018

First African child vaccinated with new typhoid conjugate vaccine

Today the University of Maryland School of Medicine's Center for Vaccine Development is proud to be part of vaccine history in Africa.

22 Feb 2018

People with major depressive disorder have reduced arginine levels, study shows

People suffering from major depressive disorder, MDD, have reduced arginine levels, a new study from the University of Eastern Finland shows. Arginine is an amino acid which the body uses to produce, e.g., nitric oxide.

21 Feb 2018

Clinical trial shows safety of promising TSRI stroke drug

A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps Research Institute.

20 Feb 2018

Gout medication may help improve heart function in adult patients

Researchers at the University of Cincinnati College of Medicine have shown that probenecid, a drug long used to treat gout, may be able to improve heart function in adult patients who experience heart failure.

20 Feb 2018

Clinical trial studying type 1 diabetes reaches full enrollment

A clinical trial studying type 1 diabetes has reached full enrollment. The Sanford Project: T-Rex Study, a Phase 2 clinical trial conducted collaboratively by Sanford Health and Caladrius Biosciences, Inc., has completed enrollment of 110 children with type 1 diabetes. The study started with two sites at Sanford Health in Sioux Falls, South Dakota, and Fargo, North Dakota, and expanded to 13 additional sites across the United States.

19 Feb 2018

Psoriasis drug also effective at reducing aortic inflammation

Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.

18 Feb 2018

New medication improves motor function in children with later-onset spinal muscular atrophy

Children with later-onset spinal muscular atrophy (SMA) were more likely to show gains in motor function when treated with a new medication compared to children receiving a sham procedure, according to a study published today in the New England Journal of Medicine.

15 Feb 2018

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings

29 Jan 2018

Researchers test new anti-malaria medication

An international research team has conducted successful phase II clinical tests of a new anti-malaria medication. The treatment led to a cure in 83 cases.

19 Jan 2018

World’s first vaccine relieves grass pollen allergy symptoms by at least 25%, study shows

Around 400 million people world-wide suffer in some form or other from a grass pollen allergy (rhinitis) - with the usual symptoms such as a runny nose, cough and severe breathing problems.

18 Jan 2018

New universal flu vaccine moves to clinical trial phase and could be a reality soon

Alphabet’s venture arm called Google Ventures earlier is one of the supporters of a mega projects that is developing a vaccine for flu that is safe and effective. Vaccitech from United Kingdom is working towards development of the vaccine and Alphabet has shown its support by contributing $27.6 million in new funding. The funds would be used conduct clinical trials and try the new vaccine.

16 Jan 2018

ASIT biotech’s new article presents clinical results of gp - ASIT+ for treatment of grass pollen-induced rhinitis

ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company specialized in immunotherapy products for the treatment of allergies, is publishing a new article in the prestigious science journal ALLERGY.

16 Jan 2018

Generic skin cream may reduce squamous cell carcinoma risk

New results from a clinical trial involving more than 900 military veterans at high risk for keratinocyte carcinoma skin cancer provides evidence that using the generic skin cream fluorouacil 5 percent for two to four weeks may reduce the risk of a squamous cell carcinoma (SCC) needing surgery by 75 percent within a year.

3 Jan 2018

Nanobiotix receives FDA approval for first immuno-oncology trial

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).

26 Dec 2017

Novel drug shows promise in treating metastatic kidney cancer

Metastatic kidney cancer remains largely incurable. Despite a dozen treatments and several immunotherapies, survival rates beyond 5 years remain around 10 percent.

21 Dec 2017

FDA proposes new approach to the regulation of unapproved, potentially harmful homeopathic drugs

The U.S. Food and Drug Administration (FDA) is proposing a new, risk-based enforcement approach to the regulation of homeopathic products that are potentially the most harmful to people.

19 Dec 2017